Stock Evaluator: uniQure N.V. (QURE)

uniQure N.V. QURE

$47.97 -0.65 -1.34%
August 17, 2026 4:00:00 PM EST November 10, 2021 Volume: 838,542
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Commentary & Analysis


Financial Summary

Share Statistics QURE Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3,327.5 $272.4 60%
Shares Out (Mil) 66.2 54.2 54%
Institutional Ownership 97.9% 92.8% 76%
Float (Mil) 57.5 39.7 50%
Beta 0.94 0.94 57%
Avg Daily Volume (000s) 1,093 500 71%
Price Change
(52-week)
204.0% 57.9% 97%
Growth QURE Industry
Median
Percentile
(All Stocks)
Sales (5yr) (15.6%) 13.6% 3%
Net Income (5yr) (9.7%) (9.9%) 29%
EPS (5yr) (4.2%) 16.0% 26
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 14.5% (15.6%) 72%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 9 9 9
Current EPS ($0.953) ($3.984) ($3.005)
Month Ago EPS ($0.940) ($3.658) ($2.925)
# Rev Up 2 0 2
# Rev Down 0 1 1
Three Months Ago EPS ($0.871) ($3.465) ($2.822)
Year/Year Chg (22.1%) 15.1% (82.5%)
Financials QURE Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $19 $37 13%
Net Income (TTM) (Mil) ($252) ($43) 6%
EPS (TTM) ($4.036) ($1.400) 9%
Operating Cash Flow (TTM) (Mil) ($161) ($31) 4%
Net Cash Flow (TTM) (Mil) $159 $2 82%
Long-Term Debt (Q1) (Mil) $549 $4 60%
Enterprise Value (Q1) (Mil) $2,772 $229 52%
Valuation QURE Industry
Median
Percentile
(All Stocks)
P/B 10.27 2.78 90%
P/E na 18.4 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.9 na
Ratios QURE Industry
Median
Percentile
(All Stocks)
Gross Margin (614.3%) 64.5% 0%
Net Margin na (75.9%) na
ROA (32.1%) (47.3%) 16%
ROE (157.6%) (54.1%) 5%
Liabilities to Assets 67.1% 29.9% 63%
F-Score 4 3 33%

uniQure N.V. did not pass any screens on 8/17/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors